In-Vitro Efficacy of Synergistic Antibiotic Combinations in Multidrug Resistant Pseudomonas Aeruginosa Strains

Basit Öğe Kaydı
dc.authoridDundar, Devrim/0000-0003-2073-7168
dc.contributor.authorDundar, Devrim
dc.contributor.authorOtkun, Metin
dc.date.accessioned2025-01-27T20:16:32Z
dc.date.available2025-01-27T20:16:32Z
dc.date.issued2010
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose: Combination antibiotic treatment is preferred in nosocomial infections caused by Pseudomonas aeruginosa (P. aeruginosa). In vitro synergism tests were used to choose the combinations which might be used in clinic. The aim of this study was to investigate the synergistic efficacy of synergistic antibiotic combinations in multidrug resistant P. aeruginosa strains. Materials and Methods: Synergistic efficacies of ceftazidime-tobramycin, piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-isepamycin, imipenem-ciprofloxacin and ciprofloxacin-tobramycin combinations were investigated by checkerboard technique in 12 multiple-resistant and 13 susceptible P. aeruginosa strains. Results: The ratios of synergy were observed in ceftazidime-tobramycin and piperacillin/tazobactam-tobramycin combinations as 67%, and 50%, respectively, in resistant strains, whereas synergy was not detected in other combinations. The ratios of synergy were observed in ceftazidime-tobramycin, piperacilllin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-ciprofloxacin and imipenem-isepamycin combinations as 31%, 46%, 15%, 8%, 8%, and respectively, in susceptible strains, whereas synergy was not detected in ciprofloxacin-tobramycin combination. Antagonism was not observed in any of the combinations. Conclusion: Although the synergistic ratios were high in combinations with ceftazidime or piperacillin/tazobactam and tobramycin, die concentrations in these combinations could not usually reach clinically available levels. Thus, the solution of the problems caused by multiple resistant P. aeruginosa should be based on the prevention of the development of resistance and spread of the causative agent between patients.
dc.identifier.doi10.3349/ymj.2010.51.1.111
dc.identifier.endpage116
dc.identifier.issn0513-5796
dc.identifier.issn1976-2437
dc.identifier.issue1
dc.identifier.pmid20046523
dc.identifier.scopus2-s2.0-75749107905
dc.identifier.scopusqualityQ1
dc.identifier.startpage111
dc.identifier.urihttps://doi.org/10.3349/ymj.2010.51.1.111
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21274
dc.identifier.volume51
dc.identifier.wosWOS:000273495500017
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherYonsei Univ Coll Medicine
dc.relation.ispartofYonsei Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectPseudomonas aeruginosa
dc.subjectsynergy
dc.subjectantimicrobial
dc.subjectcombination
dc.titleIn-Vitro Efficacy of Synergistic Antibiotic Combinations in Multidrug Resistant Pseudomonas Aeruginosa Strains
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu